康基医疗私有化进展：寄发私有化计划文件，股东大会于11月10日表决

Core Viewpoint - The article discusses the privatization plan of Kangji Medical (9997.HK) initiated by a consortium led by TPG and other investors, highlighting the potential benefits for shareholders amidst market volatility and geopolitical risks [2][4]. Group 1: Privatization Details - On October 13, Kangji Medical announced the publication of a privatization proposal document, marking a critical phase in the transaction [2]. - The privatization is led by a consortium including TPG's funds, NewQuest, Qatar's sovereign fund Al-Rayyan Holding, and the founding entity, with a cash buyout price of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion (around HKD 11.2 billion) [4]. - The independent board committee, after consulting with independent financial advisors, deemed the privatization plan fair and reasonable, recommending shareholders to vote in favor [4]. Group 2: Timeline and Process - A court meeting and a special shareholder meeting are scheduled for November 10, with results expected by 7:00 PM the same day. If approved, subsequent procedures will include a Cayman court hearing, capital reduction, share cancellation, and cash payment, anticipated to take effect by December 5, with formal delisting on December 9 [4]. - Kangji Medical, established in 2004 and listed on the Hong Kong Stock Exchange in 2020, is the largest minimally invasive surgical instrument and consumables platform in China, serving over 3,500 hospitals, including more than 1,000 top-tier hospitals, with operations in over 90 countries and regions [4]. Group 3: Market Context - The company has faced low average turnover rates over the past two years, leading to liquidity challenges. The privatization is seen as a way to attract long-term strategic investments rather than focusing on short-term performance pressures [5]. - As of October 13, Kangji Medical's stock price was HKD 8.9, with a market capitalization of HKD 10.7 billion [6].